This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

AISF position paper on HCV in immunocompromised patients

Bruno R.;
2019-01-01

Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
2019
Esperti anonimi
Inglese
Internazionale
STAMPA
51
1
10
23
14
HCV; Immunocompromised patients; Organ transplant; Antiviral Agents; Comorbidity; Hepatitis C, Chronic; Humans; Immunocompetence; Italy; Neoplasms; Transplant Recipients; Immunocompromised Host
83
info:eu-repo/semantics/article
262
Marzano, A.; Angelucci, E.; Astegiano, M.; Baratelli, C.; Biancone, L.; Bironzo, P.; Brancaccio, G.; Brunetto, M. R.; Bruno, R.; Burra, P.; Cabras, M....espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1403794
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact